TY - JOUR
T1 - Strategies for multivessel revascularization in patients with diabetes
AU - Farkouh, Michael E
AU - Domanski, Michael
AU - Sleeper, Lynn A
AU - Siami, Flora S
AU - Dangas, George
AU - Mack, Michael
AU - Yang, May
AU - Cohen, David J
AU - Rosenberg, Yves
AU - Solomon, Scott D
AU - Desai, Akshay S
AU - Gersh, Bernard J
AU - Magnuson, Elizabeth A
AU - Lansky, Alexandra
AU - Boineau, Robin
AU - Weinberger, Jesse
AU - Ramanathan, Krishnan
AU - Sousa, J Eduardo
AU - Rankin, Jamie
AU - Bhargava, Balram
AU - Buse, John
AU - Hueb, Whady
AU - Smith, Craig R
AU - Muratov, Victoria
AU - Bansilal, Sameer
AU - King, Spencer
AU - Bertrand, Michel
AU - Fuster, Valentin
AU - FREEDOM Trial Investigators
AU - Hankey, Graeme John
PY - 2012/12/20
Y1 - 2012/12/20
N2 - BACKGROUND: In some randomized trials comparing revascularization strategies for patients with diabetes, coronary-artery bypass grafting (CABG) has had a better outcome than percutaneous coronary intervention (PCI). We sought to discover whether aggressive medical therapy and the use of drug-eluting stents could alter the revascularization approach for patients with diabetes and multivessel coronary artery disease.METHODS: In this randomized trial, we assigned patients with diabetes and multivessel coronary artery disease to undergo either PCI with drug-eluting stents or CABG. The patients were followed for a minimum of 2 years (median among survivors, 3.8 years). All patients were prescribed currently recommended medical therapies for the control of low-density lipoprotein cholesterol, systolic blood pressure, and glycated hemoglobin. The primary outcome measure was a composite of death from any cause, nonfatal myocardial infarction, or nonfatal stroke.RESULTS: From 2005 through 2010, we enrolled 1900 patients at 140 international centers. The patients' mean age was 63.1±9.1 years, 29% were women, and 83% had three-vessel disease. The primary outcome occurred more frequently in the PCI group (P=0.005), with 5-year rates of 26.6% in the PCI group and 18.7% in the CABG group. The benefit of CABG was driven by differences in rates of both myocardial infarction (P<0.001) and death from any cause (P=0.049). Stroke was more frequent in the CABG group, with 5-year rates of 2.4% in the PCI group and 5.2% in the CABG group (P=0.03).CONCLUSIONS: For patients with diabetes and advanced coronary artery disease, CABG was superior to PCI in that it significantly reduced rates of death and myocardial infarction, with a higher rate of stroke. (Funded by the National Heart, Lung, and Blood Institute and others; FREEDOM ClinicalTrials.gov number, NCT00086450.).
AB - BACKGROUND: In some randomized trials comparing revascularization strategies for patients with diabetes, coronary-artery bypass grafting (CABG) has had a better outcome than percutaneous coronary intervention (PCI). We sought to discover whether aggressive medical therapy and the use of drug-eluting stents could alter the revascularization approach for patients with diabetes and multivessel coronary artery disease.METHODS: In this randomized trial, we assigned patients with diabetes and multivessel coronary artery disease to undergo either PCI with drug-eluting stents or CABG. The patients were followed for a minimum of 2 years (median among survivors, 3.8 years). All patients were prescribed currently recommended medical therapies for the control of low-density lipoprotein cholesterol, systolic blood pressure, and glycated hemoglobin. The primary outcome measure was a composite of death from any cause, nonfatal myocardial infarction, or nonfatal stroke.RESULTS: From 2005 through 2010, we enrolled 1900 patients at 140 international centers. The patients' mean age was 63.1±9.1 years, 29% were women, and 83% had three-vessel disease. The primary outcome occurred more frequently in the PCI group (P=0.005), with 5-year rates of 26.6% in the PCI group and 18.7% in the CABG group. The benefit of CABG was driven by differences in rates of both myocardial infarction (P<0.001) and death from any cause (P=0.049). Stroke was more frequent in the CABG group, with 5-year rates of 2.4% in the PCI group and 5.2% in the CABG group (P=0.03).CONCLUSIONS: For patients with diabetes and advanced coronary artery disease, CABG was superior to PCI in that it significantly reduced rates of death and myocardial infarction, with a higher rate of stroke. (Funded by the National Heart, Lung, and Blood Institute and others; FREEDOM ClinicalTrials.gov number, NCT00086450.).
KW - Aged
KW - Angioplasty, Balloon, Coronary
KW - Cardiovascular Diseases/mortality
KW - Coronary Artery Bypass
KW - Coronary Artery Disease/complications
KW - Diabetes Complications/surgery
KW - Drug-Eluting Stents
KW - Female
KW - Humans
KW - Kaplan-Meier Estimate
KW - Male
KW - Middle Aged
KW - Myocardial Infarction/epidemiology
KW - Stroke/epidemiology
U2 - 10.1056/NEJMoa1211585
DO - 10.1056/NEJMoa1211585
M3 - Article
C2 - 23121323
VL - 367
SP - 2375
EP - 2384
JO - The New England Journal of Medicine
JF - The New England Journal of Medicine
SN - 0028-4793
IS - 25
ER -